Forxiga, a product of the pharmaceutical company AstraZeneca, is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. It functions by blocking the SGLT2 protein in the kidneys, which is responsible for the reabsorption of glucose back into the bloodstream. By inhibiting this process, Forxiga helps to reduce blood glucose levels by promoting the excretion of excess glucose through urine.
Forxiga 10 is typically prescribed at a starting dose of 10mg once daily, taken orally in the morning with or without food. This dosage is designed to maintain optimal blood glucose control and is generally well-tolerated by most patients.
